Contact allergenic potency

Correlation of human and local lymph node assay data

G. Frank Gerberick, Michael K. Robinson, Cindy A. Ryan, Rebecca J. Dearman, Ian Kimber, David A. Basketter, Zoe Wright, James Marks

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

Background: Effective toxicologic evaluation of skin sensitization requires that potential contact allergens are identified and that the likely risks of sensitization among exposed populations are assessed. By definition, chemicals that are classified as contact sensitizers have the capacity to cause allergic contact dermatitis (ACD) in humans. However, this hazard is not an all-or-nothing phenomenon; clear dose-response relationships can be discerned and thresholds identified for both the induction of sensitization and the elicitation of ACD. Commonly, these parameters are grouped under the heading of potency, the determination of which is vital for risk assessment. Preclinical testing for sensitization potential is critically important for hazard assessment before human exposure. The murine local lymph node assay (LLNA) is the most recently accepted test method for sensitization hazard assessment. Objective: The aim was to compare potency estimations derived from LLNA data with clinical determinations of relative potency based on human data. Methods: No-effect levels (NOELs) for a range of 21 chemicals were determined from nondiagnostic human repeat patch test studies as reported in the literature. These levels were compared with LLNA EC3 values, the estimated concentration required to produce a 3-fold increase (positive response) in draining lymph node cell (LNC) proliferative activity. Results: Using available human repeat patch test data, together with expert judgment, the compounds were classified as strong, moderate, weak, extremely weak, or nonsensitizing. Additionally, the potency of each chemical was classified independently based on its LLNA EC3 value. The results show clearly that LLNA EC3 values are very comparable with the NOELs calculated from the literature. Moreover, the potency rankings based upon LLNA EC3 data support their human classification. Conclusion: The present investigations show that the LLNA can be used to provide quantitative estimates of relative skin sensitizing potency EC3 values that correlate closely with NOELs established from human repeat patch testing and from our clinical experience.

Original languageEnglish (US)
Pages (from-to)156-161
Number of pages6
JournalUnknown Journal
Volume12
Issue number3
DOIs
StatePublished - Jan 1 2001

Fingerprint

Local Lymph Node Assay
Allergic Contact Dermatitis
Patch Tests
Skin
Allergens
Lymph Nodes

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Gerberick, G. F., Robinson, M. K., Ryan, C. A., Dearman, R. J., Kimber, I., Basketter, D. A., ... Marks, J. (2001). Contact allergenic potency: Correlation of human and local lymph node assay data. Unknown Journal, 12(3), 156-161. https://doi.org/10.1053/ajcd.2001.23926
Gerberick, G. Frank ; Robinson, Michael K. ; Ryan, Cindy A. ; Dearman, Rebecca J. ; Kimber, Ian ; Basketter, David A. ; Wright, Zoe ; Marks, James. / Contact allergenic potency : Correlation of human and local lymph node assay data. In: Unknown Journal. 2001 ; Vol. 12, No. 3. pp. 156-161.
@article{46f97d5e70f04cbfa238ede90f80ab9e,
title = "Contact allergenic potency: Correlation of human and local lymph node assay data",
abstract = "Background: Effective toxicologic evaluation of skin sensitization requires that potential contact allergens are identified and that the likely risks of sensitization among exposed populations are assessed. By definition, chemicals that are classified as contact sensitizers have the capacity to cause allergic contact dermatitis (ACD) in humans. However, this hazard is not an all-or-nothing phenomenon; clear dose-response relationships can be discerned and thresholds identified for both the induction of sensitization and the elicitation of ACD. Commonly, these parameters are grouped under the heading of potency, the determination of which is vital for risk assessment. Preclinical testing for sensitization potential is critically important for hazard assessment before human exposure. The murine local lymph node assay (LLNA) is the most recently accepted test method for sensitization hazard assessment. Objective: The aim was to compare potency estimations derived from LLNA data with clinical determinations of relative potency based on human data. Methods: No-effect levels (NOELs) for a range of 21 chemicals were determined from nondiagnostic human repeat patch test studies as reported in the literature. These levels were compared with LLNA EC3 values, the estimated concentration required to produce a 3-fold increase (positive response) in draining lymph node cell (LNC) proliferative activity. Results: Using available human repeat patch test data, together with expert judgment, the compounds were classified as strong, moderate, weak, extremely weak, or nonsensitizing. Additionally, the potency of each chemical was classified independently based on its LLNA EC3 value. The results show clearly that LLNA EC3 values are very comparable with the NOELs calculated from the literature. Moreover, the potency rankings based upon LLNA EC3 data support their human classification. Conclusion: The present investigations show that the LLNA can be used to provide quantitative estimates of relative skin sensitizing potency EC3 values that correlate closely with NOELs established from human repeat patch testing and from our clinical experience.",
author = "Gerberick, {G. Frank} and Robinson, {Michael K.} and Ryan, {Cindy A.} and Dearman, {Rebecca J.} and Ian Kimber and Basketter, {David A.} and Zoe Wright and James Marks",
year = "2001",
month = "1",
day = "1",
doi = "10.1053/ajcd.2001.23926",
language = "English (US)",
volume = "12",
pages = "156--161",
journal = "[No source information available]",
issn = "0042-1215",
number = "3",

}

Gerberick, GF, Robinson, MK, Ryan, CA, Dearman, RJ, Kimber, I, Basketter, DA, Wright, Z & Marks, J 2001, 'Contact allergenic potency: Correlation of human and local lymph node assay data', Unknown Journal, vol. 12, no. 3, pp. 156-161. https://doi.org/10.1053/ajcd.2001.23926

Contact allergenic potency : Correlation of human and local lymph node assay data. / Gerberick, G. Frank; Robinson, Michael K.; Ryan, Cindy A.; Dearman, Rebecca J.; Kimber, Ian; Basketter, David A.; Wright, Zoe; Marks, James.

In: Unknown Journal, Vol. 12, No. 3, 01.01.2001, p. 156-161.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Contact allergenic potency

T2 - Correlation of human and local lymph node assay data

AU - Gerberick, G. Frank

AU - Robinson, Michael K.

AU - Ryan, Cindy A.

AU - Dearman, Rebecca J.

AU - Kimber, Ian

AU - Basketter, David A.

AU - Wright, Zoe

AU - Marks, James

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Background: Effective toxicologic evaluation of skin sensitization requires that potential contact allergens are identified and that the likely risks of sensitization among exposed populations are assessed. By definition, chemicals that are classified as contact sensitizers have the capacity to cause allergic contact dermatitis (ACD) in humans. However, this hazard is not an all-or-nothing phenomenon; clear dose-response relationships can be discerned and thresholds identified for both the induction of sensitization and the elicitation of ACD. Commonly, these parameters are grouped under the heading of potency, the determination of which is vital for risk assessment. Preclinical testing for sensitization potential is critically important for hazard assessment before human exposure. The murine local lymph node assay (LLNA) is the most recently accepted test method for sensitization hazard assessment. Objective: The aim was to compare potency estimations derived from LLNA data with clinical determinations of relative potency based on human data. Methods: No-effect levels (NOELs) for a range of 21 chemicals were determined from nondiagnostic human repeat patch test studies as reported in the literature. These levels were compared with LLNA EC3 values, the estimated concentration required to produce a 3-fold increase (positive response) in draining lymph node cell (LNC) proliferative activity. Results: Using available human repeat patch test data, together with expert judgment, the compounds were classified as strong, moderate, weak, extremely weak, or nonsensitizing. Additionally, the potency of each chemical was classified independently based on its LLNA EC3 value. The results show clearly that LLNA EC3 values are very comparable with the NOELs calculated from the literature. Moreover, the potency rankings based upon LLNA EC3 data support their human classification. Conclusion: The present investigations show that the LLNA can be used to provide quantitative estimates of relative skin sensitizing potency EC3 values that correlate closely with NOELs established from human repeat patch testing and from our clinical experience.

AB - Background: Effective toxicologic evaluation of skin sensitization requires that potential contact allergens are identified and that the likely risks of sensitization among exposed populations are assessed. By definition, chemicals that are classified as contact sensitizers have the capacity to cause allergic contact dermatitis (ACD) in humans. However, this hazard is not an all-or-nothing phenomenon; clear dose-response relationships can be discerned and thresholds identified for both the induction of sensitization and the elicitation of ACD. Commonly, these parameters are grouped under the heading of potency, the determination of which is vital for risk assessment. Preclinical testing for sensitization potential is critically important for hazard assessment before human exposure. The murine local lymph node assay (LLNA) is the most recently accepted test method for sensitization hazard assessment. Objective: The aim was to compare potency estimations derived from LLNA data with clinical determinations of relative potency based on human data. Methods: No-effect levels (NOELs) for a range of 21 chemicals were determined from nondiagnostic human repeat patch test studies as reported in the literature. These levels were compared with LLNA EC3 values, the estimated concentration required to produce a 3-fold increase (positive response) in draining lymph node cell (LNC) proliferative activity. Results: Using available human repeat patch test data, together with expert judgment, the compounds were classified as strong, moderate, weak, extremely weak, or nonsensitizing. Additionally, the potency of each chemical was classified independently based on its LLNA EC3 value. The results show clearly that LLNA EC3 values are very comparable with the NOELs calculated from the literature. Moreover, the potency rankings based upon LLNA EC3 data support their human classification. Conclusion: The present investigations show that the LLNA can be used to provide quantitative estimates of relative skin sensitizing potency EC3 values that correlate closely with NOELs established from human repeat patch testing and from our clinical experience.

UR - http://www.scopus.com/inward/record.url?scp=0034820655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034820655&partnerID=8YFLogxK

U2 - 10.1053/ajcd.2001.23926

DO - 10.1053/ajcd.2001.23926

M3 - Article

VL - 12

SP - 156

EP - 161

JO - [No source information available]

JF - [No source information available]

SN - 0042-1215

IS - 3

ER -

Gerberick GF, Robinson MK, Ryan CA, Dearman RJ, Kimber I, Basketter DA et al. Contact allergenic potency: Correlation of human and local lymph node assay data. Unknown Journal. 2001 Jan 1;12(3):156-161. https://doi.org/10.1053/ajcd.2001.23926